Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Alterations in Muscle Tone ll

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

From Severe Neonatal Encephalopathy to Slowly Neurologic Progressive Disease: Pyruvate Dehydrogenase Deficiency Related to <i>PDHA1</i> Variants.

Journal of child neurology·2025

Same author

[Migraine headaches: What is new in treatment?]

Medicina·2025

Same author

[Malformations of cortical development: what's new?]

Medicina·2024

Same author

Experience of an interdisciplinary management for pediatric Moyamoya disease: application of a novel Hemispheric Surgical Score.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2024

Same author

[Arterial ischemic stroke in childhood].

Medicina·2023

Same author

[Malformations of cortical development and epilepsy].

Medicina·2019

Search research articles

Related Experiment Video

Updated: May 7, 2026

Visualizing the DNA Damage Response in Purkinje Cells Using Cerebellar Organotypic Cultures

Visualizing the DNA Damage Response in Purkinje Cells Using Cerebellar Organotypic Cultures

Published on: December 27, 2024

[Therapeutic developments in chronic ataxias].

María Celeste Buompadre¹

¹Servicio de Neurología Infantil, Hospital de Pediatría Prof. Dr. J. P. Garrahan, Buenos Aires.

|September 28, 2013

Summary

Autosomal recessive cerebellar ataxias are inherited neurological disorders often starting before age 20. While specific treatments are limited, early intervention with targeted therapies can improve outcomes for some patients.

Keywords:

antioxidant agents cerebellar ataxia corticosteroid treatment vitamin

More Related Videos

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

Related Experiment Videos

Last Updated: May 7, 2026

Visualizing the DNA Damage Response in Purkinje Cells Using Cerebellar Organotypic Cultures

Visualizing the DNA Damage Response in Purkinje Cells Using Cerebellar Organotypic Cultures

Published on: December 27, 2024

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

Area of Science:

Neurology
Genetics
Metabolic Disorders

Context:

Autosomal recessive cerebellar ataxias (ARCAs) are a subset of inherited ataxias.
Characterized by cerebellar and spinal cord degeneration or abnormal development.
Typically present with onset before 20 years of age.

Purpose:

To review current treatment strategies for autosomal recessive cerebellar ataxias.
To highlight specific treatments for metabolically-linked ARCAs.
To discuss potential therapeutic approaches for other ARCA subtypes.

Summary:

Specific treatments exist for ARCAs with known metabolic defects (e.g., abetalipoproteinemia, vitamin E deficiency, cerebrotendinous xanthomatosis) using dietary changes and supplements.
For Friedreich's ataxia, iron chelators and antioxidants are explored to manage mitochondrial iron overload.
Corticosteroids may alleviate symptoms in ataxia telangiectasia, and Coenzyme Q10 supplementation can benefit related deficiencies.

Impact:

Early diagnosis and treatment initiation are crucial for potentially better drug responses.
Dietary modifications and specific supplements can alter disease progression in certain ARCAs.
Ongoing research into novel therapies like iron chelators and antioxidants offers hope for managing complex neurological conditions.